Orchid Pharma has informed that the Board of Directors of the Company, in its meeting held today, December 01, 2022 (commenced at 12.00 pm and concluded at 02:30 pm), has considered and approved the issuance of Equity Shares up to Rs 500 crores including premium through Qualified Institutional Placement under Chapter VI of SEBI ICDR Regulations subject to the approval of the shareholders of the Company. Also enclosed the disclosures in ANNEXURE-A pursuant to aforementioned Regulation read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015. This intimation shall also be available on the Company’s website at www.orchidpharma.com.
The above information is a part of company’s filings submitted to BSE.
